Puzolcabtagene Autoleucel Approved in China For Pediatric B-Cell Acute Lymphoblastic Leukemia
08/11/2025
On November 7, 2025, the National Medical Products Administration (NMPA) officially approved Puzolcabtagene Autoleucel Injection, an independently developed Class I biological drug, for marketing in China for the treatment for